Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oyster Point Pharma, Inc. (OYST)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
| Cost of goods sold | 24.1% | 27.9% | 12.4% | 23.1% | 0.0% | | | |
| Gross profit | 75.9% | 72.1% | 87.6% | 76.9% | 100.0% | | | |
| Sales and marketing | 395.2% | 598.8% | 997.3% | 828.1% | 101.3% | | | |
| Research and development | 70.0% | 99.4% | 173.1% | 82.8% | 34.6% | | | |
| General and administrative | 217.3% | 298.4% | 478.3% | -243.7% | 57.6% | | | |
| Depreciation | 1.3% | 2.4% | 2.7% | 0.8% | 0.2% | | | |
| EBIT | -606.6% | -924.5% | -1561.1% | -590.4% | -93.5% | | | |
| Pre-tax income | -657.3% | -1064.2% | -1771.2% | -637.7% | -98.5% | | | |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| Net income | -657.3% | -1064.2% | -1771.2% | -637.7% | -98.5% | | | |
|